Mushroom compound may revive immune system in cancer survivors
NCT ID NCT07258160
First seen Dec 04, 2025 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tests a mushroom-derived supplement called cordycepin (PRaG-1) in 127 adults who had solid tumors and are now cancer-free for at least six months after radiation or chemotherapy, but have low levels of CD8+ immune cells. Participants take the supplement for two weeks, and those who respond will either continue it or switch to a placebo for another two weeks. The goal is to see if cordycepin can safely raise CD8+ cell counts and help maintain immune health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.